• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
COVID-19 Vaccination Recommendations for 2024-2025 in Korea.韩国2024 - 2025年新冠疫苗接种建议
Infect Chemother. 2024 Dec;56(4):453-460. doi: 10.3947/ic.2024.0142.
2
[Technical guidelines for seasonal influenza vaccination in China (2023-2024)].《中国季节性流感疫苗接种技术指南(2023—2024年)》
Zhonghua Liu Xing Bing Xue Za Zhi. 2023 Oct 10;44(10):1507-1530. doi: 10.3760/cma.j.cn112338-20230908-00139.
3
[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].《中国季节性流感疫苗接种技术指南(2022—2023年)》
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Oct 6;56(10):1356-1386. doi: 10.3760/cma.j.cn112150-20220825-00840.
4
[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].《中国季节性流感疫苗接种技术指南(2022—2023年)》
Zhonghua Liu Xing Bing Xue Za Zhi. 2022 Oct 10;43(10):1515-1544. doi: 10.3760/cma.j.cn112338-20220825-00734.
5
Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents.养老院居民接种XBB.1.5疫苗后对既往SARS-CoV-2毒株和JN.1变体产生的广泛免疫原性。
medRxiv. 2024 Mar 29:2024.03.21.24303684. doi: 10.1101/2024.03.21.24303684.
6
[Technical guidelines for seasonal influenza vaccination in China (2021-2022)].《中国季节性流感疫苗接种技术指南(2021—2022年)》
Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Oct 10;42(10):1722-1749. doi: 10.3760/cma.j.cn112338-20210913-00732.
7
[Technical guidelines for seasonal influenza vaccination in China (2020-2021)].《中国季节性流感疫苗接种技术指南(2020—2021年)》
Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Oct 6;54(10):1035-1059. doi: 10.3760/cma.j.cn112150-20200911-01198.
8
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.丹麦全国性观察研究:与 SARS-CoV-2 奥密克戎亚变体 BA.2.86 和后代 JN.1 相关的相对疫苗保护、疾病严重程度和症状。
Lancet Infect Dis. 2024 Sep;24(9):964-973. doi: 10.1016/S1473-3099(24)00220-2. Epub 2024 May 15.
9
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2(Delta)变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络,2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
10
[Technical guidelines for seasonal influenza vaccination in China (2020-2021)].《中国季节性流感疫苗接种技术指南(2020—2021年)》
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Oct 10;41(10):1555-1576. doi: 10.3760/cma.j.cn112338-20200904-01126.

本文引用的文献

1
Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-2025.《COVID-19 疫苗用于≥6 月龄人群:免疫实践咨询委员会的建议-美国,2024-2025 年》。
MMWR Morb Mortal Wkly Rep. 2024 Sep 19;73(37):819-824. doi: 10.15585/mmwr.mm7337e2.
2
Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants.JN.1 衍生的 SARS-CoV-2 SLip、FLiRT 和 KP.2 变体的中和逃逸、感染性和膜融合。
Cell Rep. 2024 Aug 27;43(8):114520. doi: 10.1016/j.celrep.2024.114520. Epub 2024 Jul 17.
3
Recommendations for Adult Immunization by the Korean Society of Infectious Diseases, 2023: Minor Revisions to the 3rd Edition.韩国传染病学会2023年成人免疫接种建议:第三版小幅修订
Infect Chemother. 2024 Jun;56(2):188-203. doi: 10.3947/ic.2023.0072.
4
Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)KP.3、LB.1和KP.2.3变体的病毒学特征
Lancet Infect Dis. 2024 Aug;24(8):e482-e483. doi: 10.1016/S1473-3099(24)00415-8. Epub 2024 Jun 27.
5
Virological characteristics of the SARS-CoV-2 KP.2 variant.严重急性呼吸综合征冠状病毒2型KP.2变体的病毒学特征。
Lancet Infect Dis. 2024 Jul;24(7):e416. doi: 10.1016/S1473-3099(24)00298-6. Epub 2024 May 20.
6
Updated Clinical Practice Guidelines for the Diagnosis and Management of Long COVID.《长新冠诊断与管理的更新临床实践指南》
Infect Chemother. 2024 Mar;56(1):122-157. doi: 10.3947/ic.2024.0024. Epub 2024 Mar 13.
7
Virological characteristics of the SARS-CoV-2 JN.1 variant.严重急性呼吸综合征冠状病毒2 JN.1变体的病毒学特征。
Lancet Infect Dis. 2024 Feb;24(2):e82. doi: 10.1016/S1473-3099(23)00813-7. Epub 2024 Jan 3.
8
Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals.第三剂mRNA新冠疫苗针对奥密克戎BA.1毒株在老年人中诱导产生的血清中和抗体滴度的大小和持续时间。
Infect Chemother. 2024 Mar;56(1):25-36. doi: 10.3947/ic.2023.0057. Epub 2023 Nov 1.
9
Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-SEROSMART): findings from national representative sample.韩国监测 SARS-CoV-2 抗体保留和传播的血清流行率研究(K-SEROSMART):全国代表性样本的结果。
Epidemiol Health. 2023;45:e2023075. doi: 10.4178/epih.e2023075. Epub 2023 Aug 17.
10
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study.北欧国家≥50 岁成年人中两价 BA.4-5 和 BA.1 mRNA 加强疫苗的有效性比较:全国队列研究。
BMJ. 2023 Jul 25;382:e075286. doi: 10.1136/bmj-2022-075286.

韩国2024 - 2025年新冠疫苗接种建议

COVID-19 Vaccination Recommendations for 2024-2025 in Korea.

作者信息

Park Wan Beom, Hwang Young Hoon, Kwon Ki Tae, Noh Ji Yun, Park Sun Hee, Song Joon Young, Choo Eun Ju, Choi Min Joo, Choi Jun Yong, Heo Jung Yeon, Choi Won Suk

机构信息

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Division of Infectious Diseases, Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.

出版信息

Infect Chemother. 2024 Dec;56(4):453-460. doi: 10.3947/ic.2024.0142.

DOI:10.3947/ic.2024.0142
PMID:39762924
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11704866/
Abstract

The Korean Society of Infectious Diseases has been regularly publishing guidelines for adult immunization since 2007. Following the release of coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023, significant changes have occurred due to the emergence of new variant strains and the waning immunity from previous vaccinations. This article provides a comprehensive update as of November 2024, incorporating the latest evidence and guidelines. Focusing on the 2024-2025 season, this article reviews vaccines currently authorized in Korea and assesses their effectiveness against the predominant JN.1 lineage variants. The updated recommendations prioritize high-risk groups, including adults aged 65 and older, individuals with underlying medical conditions, residents of facilities vulnerable to infection, pregnant women, and healthcare workers, for vaccination with updated vaccines targeting the JN.1 strain. Additionally, COVID-19 vaccination is available for all individuals aged 6 months and older. For most adults, a single-dose strategy is emphasized, while tailored schedules may be recommended for immunocompromised individuals. This update aims to optimize vaccination strategies in Korea to ensure comprehensive protection for high-risk populations.

摘要

自2007年以来,韩国传染病协会定期发布成人免疫指南。2023年发布2019冠状病毒病(COVID-19)疫苗接种建议后,由于新变异毒株的出现以及先前接种疫苗后免疫力的下降,情况发生了重大变化。本文提供截至2024年11月的全面更新内容,纳入了最新证据和指南。本文聚焦2024 - 2025年季节,回顾了韩国目前批准使用的疫苗,并评估了它们对主要的JN.1谱系变异毒株的有效性。更新后的建议将65岁及以上成年人、有基础疾病的个体、易受感染机构的居民、孕妇和医护人员等高风险人群列为优先接种针对JN.1毒株的更新疫苗的对象。此外,6个月及以上的所有人均可接种COVID-19疫苗。对于大多数成年人,强调采用单剂接种策略,而对于免疫功能低下的个体,可能会推荐量身定制的接种时间表。此次更新旨在优化韩国的疫苗接种策略,以确保为高风险人群提供全面保护。